Form 4 Iradimed Co For: 25 September By Investing.com
This article is a brief financial news item from Investing.com, stating that a Form 4 filing for Iradimed Co was released on September 25. The content largely consists of navigation links, popular searches, and market data, with the core information being the Form 4 announcement.
IRMD Form 4 Filings - iRadimed Corporation SEC Form 4
This article provides a comprehensive list of iRadimed Corporation (IRMD) Form 4 SEC filings over the last 12 months, detailing insider transactions such as stock unit conversions, sales by directors and the CEO, and equity award grants. The filings highlight sales conducted primarily through trusts linked to CEO Roger E. Susi under Rule 10b5-1 trading plans, as well as routine conversions of restricted stock units by other executives and directors. Each entry includes a Rhea-AI summary of the transaction, dates, prices, and resulting shareholdings.
IRADIMED Insiders Sell US$3.4m Of Stock, Possibly Signalling Caution
Over the last year, insiders at IRADIMED have sold shares worth US$3.4 million, which is significantly more than they bought. While this doesn't guarantee a share price decline, it suggests that some insiders may view the stock as less attractive now. Despite this, the company's shares are trading near their 52-week high, indicating strong recent performance.
IRadimed Director Joe Kiani Acquires 698 Shares Through RSU Vesting on September 23, 2026
IRadimed Director Joe Kiani acquired 698 shares of common stock on September 23, 2026, through the vesting of restricted stock units. This transaction, detailed in a Statement of Changes in Beneficial Ownership, is the first installment under the company's 2023 Equity Incentive Plan. Following the vesting, Kiani directly holds 698 shares of common stock and 1,397 remaining RSUs.
698 stock units became shares for IRADIMED (NASDAQ: IRMD) director Joe E. Kiani.
IRADIMED CORP director Joe E. Kiani converted 698 restricted stock units into 698 common shares on September 23, 2026. Following this transaction, Kiani directly holds 1,397 restricted stock units and 698 common shares. These restricted stock units, granted under the company's 2023 Equity Incentive Plan, will vest in three equal annual installments starting September 23, 2026.
One-on-one investor meetings with Iradimed's CFO are set for New York
IRADIMED CORPORATION (NASDAQ: IRMD) announced that its CFO, Jack Glenn, will host one-on-one meetings with investors at the 5th Annual ROTH Healthcare Opportunities Conference in New York on September 29, 2026. The company specializes in developing MRI-compatible medical devices, including non-magnetic IV infusion pump systems and patient vital signs monitoring systems. This participation highlights Iradimed's ongoing engagement with the investment community.
Needham initiates IRadimed stock with Hold on valuation concerns By Investing.com
Needham initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a Hold rating, citing valuation concerns despite a positive fundamental outlook. The medical device maker is considered overvalued based on its P/E ratio and EV/EBITDA multiple, even with plans for new product launches like a next-gen MRI compatible infusion pump and monitor. Although IRadimed shows strong fundamentals with a high gross profit margin and revenue growth, Needham prefers to wait for a better entry point due to the current stock valuation.
Needham initiates IRadimed stock with Hold on valuation concerns By Investing.com
Needham has initiated coverage of IRadimed Corp (NASDAQ:IRMD) with a Hold rating due to valuation concerns, despite acknowledging the medical device maker's strong fundamental outlook. The stock's current P/E ratio and EV/EBITDA multiples suggest it is overvalued according to InvestingPro analysis, with its growth potential largely priced in. IRadimed is poised for significant opportunities with new product launches, including a next-generation MRI compatible infusion pump and a new monitor, while maintaining robust financial health.
Needham initiates IRadimed stock with Hold on valuation concerns
Needham initiated coverage on IRadimed Corp (NASDAQ:IRMD) with a Hold rating due to valuation concerns, despite acknowledging the medical device maker's positive fundamental outlook and significant growth opportunities. The firm noted that IRadimed's current stock price already reflects its growth potential, prompting them to await a better entry point. The company recently surpassed Wall Street expectations in Q2 2026 financial results, with non-GAAP earnings of $0.46 per share and revenue of $20.47 million.
Director at IRADIMED (IRMD) sells 1,419 shares
IRADIMED CORP director Monty K. Allen sold a total of 1,419 shares of common stock on September 3, 2026. The sales included 1,014 shares at a weighted average price of $86.44 and 405 shares at $86.35, not under a Rule 10b5-1 trading plan. The Form 4 filing details these transactions and shows Mr. Allen's holdings after the sale to be 19,581 shares.
Iradimed director Monty Allen sells $122,621 in stock By Investing.com
Iradimed director Monty Allen sold 1,419 shares of common stock totaling $122,621 on September 3, 2026. The sales were executed at prices ranging from $86.35 to $86.44 per share, leaving Mr. Allen with 19,581 shares. This transaction follows the company's Q2 2026 financial results where IRadimed surpassed Wall Street expectations with non-GAAP earnings of $0.46 per share and $20.47 million in revenue.
Iradimed director Monty Allen sells $122,621 in stock
Iradimed director Monty K. Allen sold 1,419 shares of common stock totaling $122,621 on September 3, 2026, with prices ranging from $86.35 to $86.44 per share. Following the transactions, Mr. Allen directly holds 19,581 shares. This sale comes as the company's stock trades down roughly 14% year-to-date and recently reported exceeding Wall Street expectations for Q2 2026 earnings.
IRADIMED (NASDAQ: IRMD) director flags 1,102 RSU shares for possible sale
IRADIMED director Monty K. Allen has filed a Rule 144 notice, indicating the potential sale of IRMD common stock derived from Restricted Stock Unit (RSU) vesting related to his board service in 2024 and 2025. The filing specifies 317 RSU-related shares from 2024 vesting and 1,102 shares from 2025 vesting. This notice allows for future sales but does not guarantee that the shares will be sold.
Price to book forward of IRadimed Corp. – TRADEGATE:46K
This article presents financial information for IRadimed Corp. (TRADEGATE:46K), specifically focusing on its price-to-book forward ratio. The content is primarily a data point display from TradingView, indicating that the market is closed and no trades have occurred for this specific metric.
Rice Hall James & Associates LLC Invests $2.91 Million in iRadimed Corporation $IRMD
Rice Hall James & Associates LLC has acquired a new stake in iRadimed Corporation (NASDAQ:IRMD), purchasing 30,444 shares valued at approximately $2.91 million. This investment comes as iRadimed reports strong quarterly earnings, beating analyst expectations, and maintains a "Moderate Buy" consensus rating from Wall Street analysts, despite some recent downgrades. The company also declared a quarterly dividend of $0.20 per share.
iRadimed (NASDAQ:IRMD) Shares Cross Below 200 Day Moving Average - Time to Sell?
iRadimed (NASDAQ:IRMD) shares recently fell below their 200-day moving average, trading at $88.02 against an average of $94.77. Despite this, the company maintains a "Moderate Buy" consensus rating with a $120 target price and exceeded recent earnings and revenue estimates. iRadimed also declared a quarterly dividend of $0.20, representing an annualized yield of 0.9%.
IRMD Financials: Revenue Breakdown, Margins & Competitor Comparison
This article provides a financial overview of IRADIMED CORPORATION (IRMD), detailing its revenue breakdown, profitability margins, and a comparison with competitors. The company's main revenue source is MRI Compatible Patient Vital Signs Monitoring Systems, and it boasts strong gross, operating, and net margins, alongside a solid Return on Equity. A competitive analysis against DRTS and BVS highlights IRMD's strong market position and efficiency.
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed reported its Q2 2026 financial results, highlighting successful initial production of its new 3870 MR IV pump system and strong customer acceptance, with bookings more than double units shipped. Despite temporary gross margin compression due to manufacturing ramp-up inefficiencies, the company reaffirmed its full-year 2026 guidance, expecting improved efficiencies and continued growth in the latter half of the year, driven by the replacement of older pump systems and strong monitor sales.
iRadimed (NASDAQ:IRMD) Cut to "Hold" at Wall Street Zen
iRadimed (NASDAQ:IRMD) has been downgraded to a "Hold" rating by Wall Street Zen and Weiss Ratings, despite analysts maintaining a "Moderate Buy" consensus with an average price target of $120. The company recently surpassed quarterly earnings and revenue expectations. CEO Roger E. Susi sold 5,000 shares, and other insiders have sold shares totaling approximately $1.52 million in the last quarter, though institutional investors own a significant portion of the company.
IRadimed (IRMD) Q2 2026 Earnings Call Transcript
IRadimed reported its Q2 2026 financial results, achieving manufacturing targets for its new 3870 MR IV pump system and seeing strong customer acceptance for the four-channel quad pump. Despite a temporary decline in gross margins due to production ramp-up inefficiencies, the company reaffirmed its full-year 2026 guidance, expecting improved efficiencies and record gross margins by Q4. The company highlighted significant replacement opportunities for older pump systems and strong demand for its patient monitors, while also declaring a quarterly cash dividend.
IRADIMED (IRMD) Stock Drops As 3870 Ramp Cuts Gross Margin
IRADIMED (IRMD) stock dropped 4.6% despite posting Q2 revenue of US$20.5m and non-GAAP EPS of US$0.46. The company experienced a deliberate hit to its gross margin, which compressed from 78% to 74%, as the new 3870 MR intravenous pump moved into a higher volume production phase. While bookings outpaced shipments and full-year guidance was reaffirmed, bears remain concerned about margin risk due to the company's concentrated product set and the 3870 ramp.
IRADIMED CORPORATION to Hold Second Quarter 2026 Financial Results Conference Call on July 31, 2026
IRADIMED CORPORATION announced it will hold a conference call on July 31, 2026, to discuss its financial results for the second quarter of 2026. This press release provides informational purposes only regarding the upcoming financial disclosure. The company's stock symbol is IRMD.
IRadimed (NASDAQ:IRMD) Medical Devices Update Gains Market Attention Today
IRadimed (NASDAQ:IRMD) has gained market attention after its latest quarterly update highlighted its MRI-compatible monitoring technologies and infusion systems. The company specializes in medical devices designed for safe use in magnetic resonance imaging environments, addressing a critical need for patient monitoring and hospital safety. Its focus on product quality, regulatory compliance, and technological innovation within this niche market continues to drive demand as healthcare facilities modernize diagnostic capabilities.
IRADIMED CORP Q2 2026: Revenue $20.47M, EPS $0.41— 10-Q Summary
IRADIMED CORP reported its second-quarter 2026 results, showing flat revenue year-over-year at $20.47M, while net income and diluted EPS decreased due to margin pressure from new-product production. Revenue growth was driven by device launches and disposables, with a notable shift in geographic mix as international sales significantly increased. The company's gross margin was impacted by initial production inefficiencies, but cash from operations improved after a facility expansion.
IRadimed: Q2 Earnings Snapshot
This article provides a Q2 earnings snapshot for IRadimed. The content is concise and directly presents the company's performance for the quarter.
IRADIMED: More Than 70% of New Pump Orders Were Four-Pump Setups
IRADIMED (NASDAQ: IRMD) announced its Q2 2026 financial results, reporting $20.5 million in revenue, up 0.5% year-over-year, with GAAP diluted EPS of $0.41 and non-GAAP diluted EPS of $0.46. The company reaffirmed its full-year 2026 guidance, expecting $91.0–$96.0 million in revenue and GAAP EPS of $1.90–$2.05, and declared a quarterly cash dividend of $0.20 per share. A key highlight was the strong adoption of its new 3870 MR IV pump, with over 70% of new orders being for the four-pump "quad stack" configuration, indicating a significant product and customer mix transition.
Iradimed reports Q2 revenue $20.5M, EPS $0.41; raises dividend to $0.20 and reaffirms 2026 guidance
Iradimed (IRMD) reported Q2 revenue of $20.5 million and diluted EPS of $0.41, alongside declaring a $0.20 quarterly dividend. The company reaffirmed its Q3 and full-year 2026 revenue and GAAP EPS guidance, anticipating revenue between $91.0M–$96.0M and GAAP EPS of $1.90–$2.05 for the full year. Iradimed also launched production of its next-generation 3870 MR IV pump, expecting revenue and efficiency gains in the second half of 2026.
IRadimed: Q2 Earnings Snapshot
IRadimed Corp. (IRMD) reported a second-quarter profit of $5.2 million, or 41 cents per share, with adjusted earnings of 46 cents per share. The company generated $20.5 million in revenue for the period. Looking ahead, IRadimed forecasts third-quarter earnings between 54 and 59 cents per share on revenue of $23 million to $24.5 million, and full-year earnings of $2.09 to $2.24 per share with revenue between $91 million and $96 million.
Renaissance Technologies LLC Sells 15,700 Shares of iRadimed Corporation $IRMD
Renaissance Technologies LLC reduced its stake in iRadimed Corporation by 3.4% during the first quarter, selling 15,700 shares but still retaining 440,712 shares valued at approximately $42.4 million. Despite this sale, institutional investors collectively own 92.34% of the company, and analysts maintain a "Buy" rating with an average price target of $120. iRadimed also exceeded first-quarter earnings and revenue expectations and announced a quarterly dividend.
Iradimed earnings on deck as growth momentum faces Q2 test
Iradimed (IRMD) is set to report its second-quarter earnings, with analysts expecting $0.44 earnings per share on $20.35 million in revenue, a sequential decline from Q1. Investors will focus on the performance of its new MRI-compatible IV infusion pump, margin sustainability, and management's reaffirmation of full-year guidance. Despite anticipated Q2 softness, Wall Street maintains a "Strong Buy" rating with a target price suggesting 25% upside.
Record Results, New MRI Pump And Dividend Hike Might Change The Case For Investing In IRADIMED (IRMD)
IRADIMED (IRMD) recently reported record 2025 results, strong Q1 2026, and FDA clearance for its upgraded MRidium 3870 MRI IV infusion pump, alongside an increased quarterly dividend. These developments, particularly the new pump expected to drive replacement demand, are highlighted as potentially reshaping the investment narrative for the company. The article suggests that while the new pump presents a significant catalyst, investors should also consider the concentration risk around a single product family.
IRadimed Corp (IRMD) Financial Health: Profitability & Balance Sheet Analysis
The article provides a financial health analysis of IRadimed Corp (IRMD), noting its current financial score is 9.60, ranking it 2nd in the Healthcare Equipment & Supplies industry. It highlights the company's robust financial status and high operating efficiency, with a recent quarterly revenue of $21.98M (12.65% year-over-year increase) and a 24.12% year-over-year net profit increase. The analysis further breaks down scores for Quality of Earnings, Operational Efficiency, Growth Potential, and Shareholder Returns, indicating areas where specific data has not yet been disclosed by the company.
BlackRock (IRMD holder) discloses 5.01% IRADIMED CORP stake on Schedule 13G
BlackRock, Inc. has disclosed a passive ownership stake of 5.01% in IRADIMED CORP (IRMD) common stock, as reported on a Schedule 13G filing. As of June 30, 2026, BlackRock beneficially owned 641,128 shares, with sole voting power over 622,925 shares and sole dispositive power over all 641,128 shares. The filing specifies that while various underlying clients have rights to dividends or sale proceeds, no single client holds more than five percent of IRADIMED's outstanding common shares.
IRMD|IRadimed Corp|Price:94.860|Chg%:+0.370
This article provides a comprehensive stock analysis of IRadimed Corp (IRMD) by TradingKey, highlighting its strong fundamentals, high growth potential, and institutional confidence. The company specializes in MRI-compatible medical devices, with revenue growth averaging 27.84% annually over the last three years and high dividend payouts. Despite a high P/E ratio indicating it might be overvalued, analysts have a "Buy" rating with a target price suggesting a 24.88% upside.
IRadimed Corp (IRMD) Stock Price Live, Chart & News - TradingKey
IRadimed Corp (IRMD) is currently trading at $92.495, up 1.41%. The company specializes in MRI-compatible medical devices, including IV infusion pumps and vital signs monitors. Analysts rate IRMD as a "Buy" with a target price of $118.00, indicating a 29.37% upside.
IRadimed Corp (IRMD) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution
This article provides a detailed revenue breakdown for IRadimed Corp (IRMD), segmenting its revenue by business and by region. The data, updated on April 6, analyzes contributions from MRI-compatible IV infusion pumps, patient vital signs monitoring systems, disposables, extended warranty amortization, and ferro magnetic detection systems. It also shows a significant portion of its revenue originating from the United States compared to international markets.
IRadimed Corp (IRMD) Dividends & Stock Splits: Historical Payouts and Event Timeline
This article provides a historical overview of dividend payouts for IRadimed Corp (IRMD), detailing interim and final cash dividends with their respective record, payment, and ex-dividend dates. Over the past five years, IRadimed Corp has distributed a total of 39.46 million USD in dividends. The company's basic stock information, including market capitalization and P/E ratio, is also presented.
IRadimed Corp (IRMD) Shareholder Structure: Major Shareholders & Institutional Holdings
This article details the shareholder structure of IRadimed Corp (IRMD), outlining major individual and institutional holdings. It provides a breakdown of shareholder types, institutional shareholding trends over time, and notable shareholder activity including changes in positions. The report also lists several ETFs that hold IRMD shares.
IRadimed Corp (IRMD) Cash Flow
This article provides a detailed historical cash flow statement for IRadimed Corp (IRMD), covering quarterly and annual data for operating, investing, and financing activities. It presents financial figures for various cash flow components from FY2013Q1 through FY2026Q1, along with year-over-year percentage changes. The report also includes an FAQ section defining different types of cash flow and summarizing IRadimed Corp's recent performance in these areas.
IRMD|IRadimed Corp|Price:94.490|Chg%:+0.630
This article presents a detailed financial overview of IRadimed Corp (IRMD), including its latest stock price, market capitalization, and P/E ratio. It provides access to the company's income statement, balance sheet, and cash flow statement, along with quarterly and annual financial indicators. The report also highlights key financial figures from the FY2025 earnings report and upcoming earnings dates and forecasts.
Before market open, IRADIMED will release Q2 results July 31
IRADIMED CORPORATION (NASDAQ: IRMD) announced it will release its Q2 2026 financial results before the market opens on Friday, July 31, 2026. Management will host a conference call at 11:00 a.m. Eastern Time the same day to discuss the results and answer questions. The company leads in developing MRI-compatible medical devices, including a non-magnetic IV infusion pump system and a patient vital signs monitoring system.
IRADIMED (IRMD) As MRI Pump Upgrade Narrative Points To Fair Value Above The Stock
IRADIMED (IRMD) stock has gained renewed attention, with analysts suggesting an 18% undervaluation and a fair value of $118 per share, largely due to the new 3870 MRI-compatible IV pump. While the upgrade narrative points to future revenue growth and a replacement cycle, the stock's current P/E ratio of 52.5x is elevated compared to industry averages. Investors are advised to consider both the growth potential from the new product and the potentially high valuation multiples.
Iradimed Corp (IRMD) Q3 2024 Earnings Report - Results, Call & Slides
Iradimed Corp (IRMD) reported its Q3 2024 earnings, beating both EPS and revenue expectations. The company posted an actual EPS of $0.43 against a consensus of $0.41, and actual revenue of $18.33 million against an expected $18.15 million, reflecting an 11.04% year-over-year growth. The earnings call took place on October 31, 2024, and the next earnings report is estimated for July 30, 2026.
Price to book forward of IRadimed Corp. – LS:A118V4
This article provides financial information for IRadimed Corp. (LS:A118V4), specifically focusing on its price-to-book forward ratio. It includes an overview of the company's financials on TradingView, such as market data provided by ICE Data Services and reference data from FactSet.
IRMD - Iradimed Corp Latest SEC Filings
This article provides the latest SEC filings and a comprehensive overview of Iradimed Corp (IRMD) financials and performance metrics. It details key financial figures such as market cap, income, sales, and various ratios, alongside stock performance, insider and institutional ownership, and analyst recommendations.
Price to book forward of IRadimed Corp. – HAN:46K
This article provides the "Price to book forward" metric for IRadimed Corp. (HAN:46K) trading on the Hannover Stock Exchange. It is a financial data point without further analysis or contextual information.
Enterprise value to revenue forward of IRadimed Corp. – HAN:46K
This article presents the enterprise value to revenue forward for IRadimed Corp. (HAN:46K) as listed on the Hannover Stock Exchange. Although the article provides no specific numerical data, it frames the company's financial metric within the context of a stock exchange listing. The content primarily focuses on navigation, market data sources, and general information about TradingView rather than detailed financial analysis of IRadimed Corp.
IRadimed Corp. Actuals & Estimates (DUS:46K)
This article provides an overview of IRadimed Corp. (DUS:46K) financial actuals and estimates, including income statement, balance sheet, and cash flow data. It covers analyst forecasts for the stock, historical price performance, upcoming earnings dates, and details on past earnings, revenue, net income, dividends, and EBITDA.
46K Forecast — Price Target — Prediction for 2027
This article provides a forecast and price target for IRadimed Corp. (46K) stock, based on analyst opinions. It includes details on maximum and minimum price estimates, past financial performance, upcoming earnings dates, dividend information, and company metrics like EBITDA and employee count. The piece also addresses frequently asked questions about trading 46K shares.
IRadimed Corp. Actuals & Estimates (NASDAQ:IRMD)
This article provides an overview of iRadimed Corporation (NASDAQ: IRMD) including financial actuals, estimates, and analyst forecasts. It covers key metrics like current stock price, historical highs and lows, market capitalization, earnings, revenue, dividends, and volatility, along with an analyst consensus and technical analysis. The company is set to release its next earnings report on July 30, 2026.
